BIOV — BioVersys AG Cashflow Statement
0.000.00%
Last trade - 00:00- CH₣151.41m
- CH₣168.37m
Annual cashflow statement for BioVersys AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | -18.3 | -18.7 |
| Depreciation | ||
| Non-Cash Items | 2.27 | 1.81 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 4.1 | 1.05 |
| Change in Prepaid Expenses | ||
| Change in Payable / Accrued Expenses | ||
| Other Operating Cash Flow | ||
| Cash from Operating Activities | -11.7 | -15.6 |
| Capital Expenditures | -0.049 | -0.038 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 3.34 | -2 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 3.29 | -2.04 |
| Financing Cash Flow Items | -0.022 | 4.73 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 7.13 | 19.2 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -2.19 | 2.24 |